Cost-benefit impact of free asthma medication provision for the pediatric population
| Autor: | Ana Carolina Fensterseifer, Frederico Orlando Friedrich, Leonardo Araújo Pinto, Renata Ongaratto, Vanessa Koltermann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male Pediatrics medicine.medical_specialty Adolescent Cost-Benefit Analysis Population 03 medical and health sciences Young Adult 0302 clinical medicine Patient Admission Cost of Illness Adrenal Cortex Hormones Cost Savings Health care Administration Inhalation medicine Humans 030212 general & internal medicine Anti-Asthmatic Agents education Child Asthma education.field_of_study business.industry Infant Admission rate Asthma medication medicine.disease Public health care Government Programs 030228 respiratory system Child Preschool Female Cost benefit business Delivery of Health Care Brazil Pediatric population |
| Zdroj: | Respiratory medicine. 164 |
| ISSN: | 1532-3064 |
| Popis: | Background Asthma is a common chronic disease in childhood, resulting in high costs for health care systems and society. As of June 2011, the Brazilian Unified Health System (SUS) provides free asthma medications for the population. This study evaluated the impact of this program on asthma admissions in the population aged 1–19 years. In addition, a cost-benefit analysis compared data before and after the introduction of the program. Methods This descriptive study was based on information from SUS Information Technology Department (DATASUS). Admission rates and costs of patients aged 1–19 years with diagnosed asthma were compared before (2008–2010) and after (2012–2017) the provision of free inhaled corticosteroid. Results The asthma admission rate reduced by 28.4% when comparing the two periods (OR 0.71; 95% CI 0.64–0.79). Children aged 1–4 years had a 27.3% reduction in asthma admissions (OR 0.72; 95% CI 0.63–0.82), while those aged 15–19 years had a 39.65% decrease (OR 0.59; 95% CI 0.37–0.95). Asthma admission costs decreased when comparing the two periods (OR 0.68; 95% CI 0.62–0.74). After the introduction of the program, mean cost savings reached US $27,865,905.08 in children aged 1–4 years and US $21,350,660.63 in those aged 5–19 years. Conclusion The economic burden of pediatric asthma on Brazil's public health care system is significant. From 2012 to 2015, free provision of inhaled corticosteroid was cost-effective in all age groups. In 2017, no cost-benefit effect was observed in this population, but asthma admission rate decreased. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect